A new FDA-approved Alzheimer's medicine slowed cognitive decline in patients

. This type of medication targets the fundamental pathophysiology of the disease and is considered a significant development in the effort to successfully treat Alzheimer's disease."Alzheimer’s disease immeasurably incapacitates the lives of those who suffer from it and has devastating effects on their loved ones," said Billy Dunn, M.D., director of the Office of Neuroscience in the FDA’s Center for Drug Evaluation and Research.

Researchers assessed Leqembi's effectiveness in a trial involving 856 patients with Alzheimer's disease. Treatment started with patients with mild cognitive impairment or mild dementia stage of the disease and confirmed the presence of amyloid beta pathology. ARIA is typically asymptomatic, but in rare cases, it can cause serious and potentially fatal complications. The most common symptom of ARIA is temporary swelling in some areas of the brain that usually resolves on its own and may be accompanied by small bleeding spots on or in the brain. However, some individuals may experience symptoms such as headaches, confusion, dizziness, changes in vision, nausea, and seizures.

I thought I saw a report it also shrunk the brain.

Health Health Latest News, Health Health Headlines

Similar News:You can also read news stories similar to this one that we have collected from other news sources.

The FDA approves an Alzheimer's drug that appears to modestly slow the diseaseThe Food and Drug Administration has approved an Alzheimer's drug that appears to modestly slow down the disease. (Story aired on Weekend Edition Saturday on Jan. 6, 2023.)
Source: NPRHealth - 🏆 144. / 63 Read more »

FDA approves Alzheimer’s drug lecanemab amid safety concernsReports of deaths potentially linked to the treatment have cast a shadow on what many hail as a landmark approval. As a former AD researcher, it appears that these two new treatments offer no advantage over tacrine - approved in 1994 for AD. Its successor, donepazil, also had similar efficacy. Both were approved with large Phase 3 trials. But profits. Huge. Why are studies on on lipid medicines like gemfibrizol, sp, being ignored for new drugs with safety issues? It seems to have promising results blocking ab without any real problems as it's well tolerated and already prescribed thousands of times. I guess it doesn't pay as well...
Source: Nature - 🏆 64. / 68 Read more »